BRPI0508428A - fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção - Google Patents

fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção

Info

Publication number
BRPI0508428A
BRPI0508428A BRPI0508428-8A BRPI0508428A BRPI0508428A BR PI0508428 A BRPI0508428 A BR PI0508428A BR PI0508428 A BRPI0508428 A BR PI0508428A BR PI0508428 A BRPI0508428 A BR PI0508428A
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical compositions
compounds
relates
production
Prior art date
Application number
BRPI0508428-8A
Other languages
English (en)
Inventor
Piet Herdewijn
Christophe Pannecouque
Tongfei Wu
Erik De Clercq
Original Assignee
Leuven K U Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43123440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508428(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0404891A external-priority patent/GB0404891D0/en
Priority claimed from GB0407712A external-priority patent/GB0407712D0/en
Application filed by Leuven K U Res & Dev filed Critical Leuven K U Res & Dev
Publication of BRPI0508428A publication Critical patent/BRPI0508428A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FOSFONATO NUCLEOSìDEOS UTILIZáVEIS COMO INGREDIENTES ATIVOS EM COMPOSIçõES FARMACêUTICAS PARA O TRATAMENTO DE INFECçõES VIRAIS E INTERMEDIáRIOS PARA SUA PRODUçãO. A presente invenção refere-se a novos fosfonato nucleosídeos, mais especificamente a novos nucleosídeos fosfonoalcóxi substituídos. A invenção também refere-se a compostos com propriedades inibidas da replicação deHlV (Vírus da imunodeficiência Humana) e a compostos com atividades antivirais com relação a outros vírus. A invenção também refere-se a métodos para a preparação de todos esses compostos e composições farmacêuticas que os compreendem. A invenção também refere-se ao uso dos ditos compostos coomo medicamento e na fabricação de um medicamento utilizável para o tratamento de sujeitos que sofrem de infecção por HlV, assim como para o tratamento de outras infecções virais, retrovirais ou lentivirais, e ao tratamento de animais que sofram de infecções por FlV, virais, retrovirais ou lentivirais.
BRPI0508428-8A 2004-03-04 2005-03-04 fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção BRPI0508428A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0404891A GB0404891D0 (en) 2004-03-04 2004-03-04 New phosponate nucleosides
US55273004P 2004-03-15 2004-03-15
GB0407712A GB0407712D0 (en) 2004-04-05 2004-04-05 New phosphonate nucleosides
PCT/BE2005/000032 WO2005085268A2 (en) 2004-03-04 2005-03-04 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production

Publications (1)

Publication Number Publication Date
BRPI0508428A true BRPI0508428A (pt) 2007-07-24

Family

ID=43123440

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508428-8A BRPI0508428A (pt) 2004-03-04 2005-03-04 fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção

Country Status (12)

Country Link
US (5) US8076310B2 (pt)
EP (2) EP2980095A1 (pt)
JP (1) JP5198055B2 (pt)
AU (1) AU2005219461B2 (pt)
BR (1) BRPI0508428A (pt)
CA (1) CA2556829C (pt)
ES (1) ES2543834T3 (pt)
IL (1) IL177658A (pt)
NZ (1) NZ549236A (pt)
PT (1) PT1720890E (pt)
SG (3) SG170825A1 (pt)
WO (1) WO2005085268A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005219461B2 (en) 2004-03-04 2010-06-17 K.U. Leuven Research & Development Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) * 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US10087209B2 (en) 2015-04-28 2018-10-02 Ku Leuven Research & Development Antiviral compounds, a process for their preparation, and their use for treating viral infections
CN111187325B (zh) * 2020-01-16 2022-09-02 郑州大学 抗肿瘤(4′R)-甲基-α-L-呋喃苏糖核苷及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
RU2183213C2 (ru) 1996-11-05 2002-06-10 ЗАО "Производственно-коммерческая ассоциация АЗТ" Модифицированные нуклеозид-5'-трифосфаты как антивирусные агенты
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
AU2002237251A1 (en) 2000-12-22 2002-07-08 K.U. Leuven Research And Development A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
JP3797262B2 (ja) 2002-04-05 2006-07-12 住友化学株式会社 変性ジエン系重合体ゴム、その製造方法及びゴム組成物
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
AU2005219461B2 (en) * 2004-03-04 2010-06-17 K.U. Leuven Research & Development Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production

Also Published As

Publication number Publication date
CA2556829A1 (en) 2005-09-15
WO2005085268A2 (en) 2005-09-15
EP1720890A2 (en) 2006-11-15
JP5198055B2 (ja) 2013-05-15
US8809520B2 (en) 2014-08-19
US20120108531A1 (en) 2012-05-03
IL177658A0 (en) 2006-12-31
SG170825A1 (en) 2011-05-30
US20140316127A1 (en) 2014-10-23
HK1093746A1 (en) 2007-03-09
SG136123A1 (en) 2007-10-29
WO2005085268A3 (en) 2005-10-13
US20070185062A1 (en) 2007-08-09
EP1720890B1 (en) 2015-05-20
US9522932B2 (en) 2016-12-20
AU2005219461B2 (en) 2010-06-17
NZ549236A (en) 2010-09-30
ES2543834T3 (es) 2015-08-24
CA2556829C (en) 2014-10-14
IL177658A (en) 2011-10-31
EP2980095A1 (en) 2016-02-03
US8501709B2 (en) 2013-08-06
PT1720890E (pt) 2015-09-09
SG10201501376XA (en) 2015-04-29
US20140039179A1 (en) 2014-02-06
AU2005219461A1 (en) 2005-09-15
US20160009750A1 (en) 2016-01-14
JP2007526258A (ja) 2007-09-13
US9249177B2 (en) 2016-02-02
US8076310B2 (en) 2011-12-13

Similar Documents

Publication Publication Date Title
BRPI0508428A (pt) fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
MX2012007410A (es) Compuestos antivirales novedosos.
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR0316407A (pt) Derivados de nucleosìdeo antiviral
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MX2007006561A (es) Uso de acido(s) graso s) omega-3 para el tratamiento de la hipercolesterolemia causada por el tratamiento antirretroviral de los pacientes infectados con vih.
EA201201265A1 (ru) Композиция (варианты), способ ее получения, резервуар, содержащий указанную композицию, и способ лечения вирусных заболеваний с ее использованием
BR112017017500A2 (pt) derivado de quinolina para uso no tratamento e prevenção de infecções virais
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BR0316264A (pt) Medicamento para tratamento de doença pulmonar obstrutiva crÈnica
BRPI0606930A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente
BR0114483A (pt) Derivado de pirazol para tratamento de doenças viróticas
WO2005012324A3 (en) Nucleobase phosphonate analogs for antiviral treatment
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BRPI0510080A (pt) combinações farmacêuticas contendo benzoxazina para tratar doenças respiratórias
RU2017130031A (ru) Композиции и способы ингибирования вирусных инфекций
BR9912142A (pt) 6-benzil-4-oxipirimidinas substituìdas, processopara sua preparação e composições contendo-as
BR112021022658A2 (pt) Outros compostos heteroaromáticos tendo atividade contra rsv
ES2103577T3 (es) Compuestos antiviricos de naftoquinona, composiciones que los contienen y utilizaciones de estos compuestos.
BRPI0513321A (pt) vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
BR0112606A (pt) Compostos tricìclicos 2-piridona úteis como inibidores de transcriptase inversa de hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]